Cargando…
Preclinical evaluation of tolvaptan and salsalate combination therapy in a Pkd1-mouse model
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic disorder and an important cause of end stage renal disease (ESRD). Tolvaptan (a V2R antagonist) is the first disease modifier drug for treatment of ADPKD, but also causes severe polyuria. AMPK activators have...
Autores principales: | Song, Xuewen, Leonhard, Wouter N., Kanhai, Anish A., Steinberg, Gregory R., Pei, York, Peters, Dorien J. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893022/ https://www.ncbi.nlm.nih.gov/pubmed/36743216 http://dx.doi.org/10.3389/fmolb.2023.1058825 |
Ejemplares similares
-
Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease
por: Leonhard, Wouter N., et al.
Publicado: (2019) -
Short salsalate administration affects cell proliferation, metabolism, and inflammation in polycystic kidney disease
por: Kanhai, Anish A., et al.
Publicado: (2023) -
Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective
por: Kanhai, Anish A., et al.
Publicado: (2020) -
Shared pathobiology identifies AMPK as a therapeutic target for obesity and autosomal dominant polycystic kidney disease
por: Iliuta, Ioan-Andrei, et al.
Publicado: (2022) -
Polycystic Kidney Disease Caused by Bilineal Inheritance of Truncating PKD1 as Well as PKD2 Mutations
por: Losekoot, Monique, et al.
Publicado: (2020)